Variables | Ureteral stone (N = 164) | Renal stone (N = 75) | p value |
---|---|---|---|
Age | |||
Median (range), years | 65 (26–90) | 69 (19–89) | 0.011 |
Gender | |||
Male/female (%) | 88/76 (53.7) | 35/40 (46.7) | 0.32 |
Body mass index | |||
Median (range), kg/m2 | 23.5 (14.3–37.2) | 23.6 (15.9–41.8) | 0.4 |
Comorbidities | |||
Diabetes yes/no (%) | 30/134 (18.3) | 24/51 (32.0) | 0.019 |
Hypertension yes/no (%) | 61/103 (37.2) | 42/33 (56.0) | 0.006 |
Hyperlipidemia yes/no (%) | 22/142 (13.4) | 14/61 (18.7) | 0.29 |
Pre-URSL sepsis | |||
Yes/no (%) | 51/113 (31.1) | 33/42 (44.0) | 0.05 |
Stone laterality | |||
Right/left/bilateral (%) | 64/94/6 (39.0)/(57.3)/(3.7) | 40/35 /0 (53.3)/(46.6)/(0) | 0.044 |
Stone size (maximal diameter) | |||
Median (range), mm | 7.2 (2.5–36.3) | 11.2 (3.1–49.2) | < 0.0001 |
Maximal hounsfield unit value | |||
Median (range), HU | 618 (163–1593) | 843 (293–1999) | < 0.0001 |
Pre-URSL renal pelvic urine culture | |||
Positive/negative/not evaluated (%) | 64/87/13 (39.0)/(53.0)/(8.0) | 32/35/8 (42.7)/(46.7)/(10.7) | 0.6 |
Pre-URSL blood culture | |||
Positive/negative/not evaluated (%) | 14/56/94 (8.5)/(34.1)/(57.3) | 13/20/42 (17.3)/(27.1)/(56.0) | 0.11 |
Pre-URSL prophylactic antibiotics | |||
Yes/no (%) | 30/134 (18.3) | 17/58 (22.7) | 0.43 |
Operation time | |||
Median (range), min | 50.0 (14–220) | 72.0 (25–147) | < 0.0001 |
Pre-URSL ureteral stenting | |||
Yes/No (%) | 149/15 (91.5) | 73/2 (97.3) | 0.07 |
Pre-URSL nephrostomy | |||
Yes/no (%) | 15/149 (8.5) | 2/73 (2.7) | 0.07 |
Period from antipyresis to URSL | |||
Median (range), days | 13.0 (1–79) | 17.0 (3–90) | 0.018 |
Pre-URSL ureteral stenting placement period | |||
Median (range), days | 20 (0–124) | 24 (2–117) | 0.11 |
Using access sheath during URSL | |||
Yes/no (%) | 74/90 (45.1) | 75/0 (100) | < 0.0001 |
Post-URSL futi | |||
Yes/no (%) | 13/151 (7.9) | 19/56 (25.3) | < 0.0001 |
Initial stone free rate | |||
Yes/no (%) | 158/6 (96.3) | 59/16 (78.7) | < 0.0001 |